[Peptic diseases].
The therapeutical acquisitions of the year 2004 are: 1. The sequential treatment of the Helicobacter pylori infection reaches an eradication rate of 95%. 2. The use of COX-2 inhibitors reduced significantly the gastrointestinal side effects of anti-inflammatory treatments. Since cardiac averse effects of certain COX-2 inhibitors had been reported, the treatments with COX-2 inhibitors came widely into question. In the case of patients with risk of NSAID induced gastrointestinal toxicity, the alternative is to return to a treatment with non specific NSAID associated to an prophylactic PPI treatment.
Vouillamoz
D
D
Service de gastro-entérologie et d'hépatologie, BH-10, CHUV, 1011 Lausanne.
Viani
F
F
Jornod
P
P
Kessler
V
V
Ehmann
T
T
Dorta
G
G
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D001471:Barrett Esophagus / Q000601:surgery; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000601:surgery; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000472:pathogenicity; D006801:Humans; D013272:Stomach Diseases / Q000188:drug therapy*; D013276:Stomach Ulcer / Q000209:etiology / Q000382:microbiology / Q000517:prevention & control
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors